The FDA has issued its Center for Drug Evaluation and Research Drug Safety Priorities Fiscal Year 2024 report, which highlights key safety-related milestones and accomplishments. The report focuses on programs and initiatives at the core of CDER’s drug safety operations, including the FDA Adverse Event Reporting System and Sentinel System.
The report covers CDER’s:
- continuing initiatives to combat the overdose crisis, including the launch of a new campaign offering free training, mentoring, and resources for health care professionals prescribing medications for opioid use disorder;
- efforts to prevent medication shortages and transparently relay information about recalls and medication safety information to the public through a variety of communication tools and outreach activities;
- robust safety monitoring program through Sentinel, work to enhance the quality of compounded medications, and partnerships to reduce medication-related harm; and
- diverse array of research conducted to identify and address drug safety risks.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!